AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Study to Characterize the Clinical Presentation and Course of Cryptosporidium in Pediatric Participants

Recruitingn/aAges 6 Months - 59 MonthsAllNovartis Pharmaceuticals
💬

In plain words

What the trial is, and whether it could suit you

This study aims to characterize the pediatric cryptosporidiosis disease profile with respect to clinical presentation.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion criteria: * Age 6 months to 59 months with diarrhea according to the World Health Organization (WHO) criteria (≥3 loose stools daily for at least 2 days) * QuikChek™ and Stool microscopy positive for Cryptosporidium at screening * Acute (\<7 days), prolonged (lasting 7-13 days), persistent (lasting 14-28 days) or chronic (lasting \>28 days) diarrheal illness (≥3 loose stools daily, as defined by WHO) at screening * Normal nutritional status, mildly-to-moderately acutely malnourished, or severely acutely malnourished according to WHO definitions (number of participants with severe acute malnutrition will be capped) at screening * Parent or primary caregiver is willing to provide informed consent and to comply with study procedures, including provision of whole stool samples at the scheduled time points and willing to be followed up to 21 days Exclusion criteria: * Bloody diarrhea, defined as diarrhea with visible blood in stool as observed by the study team member performing the screening or reported by parent/primary caregiver * Other morbidity requiring emergency medical care in an intensive care setting at the time of screening * Coincident non-enteric infection including upper or lower respiratory infection at screening * Any participant whose parent or primary caregiver is unwilling or unable to cooperate with study procedures, in the investigator's opinion * If the parent/primary caregiver managing care of the patient has travel plans out of the study area that would preclude clinic or in-home study visits during the expected study follow-up period Other protocol-defined inclusion/exclusion criteria may apply.
💊

What it tests

  • Not listed
📍

Where

4 sites
Novartis Investigative Site
Kisumu, Kenya
Novartis Investigative Site
Kuantan, Malaysia
Novartis Investigative Site
Kuala Lumpur, Malaysia
Novartis Investigative Site
Lusaka, Zambia
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy